{"product_id":"xeljanz","title":"Xeljanz","description":"\u003ch3 data-start=\"279\" data-end=\"301\"\u003eWhat is Xeljanz?\u003c\/h3\u003e\r\n\u003cp data-start=\"302\" data-end=\"733\"\u003e\u003cstrong data-start=\"302\" data-end=\"313\"\u003eXeljanz\u003c\/strong\u003e is an oral Janus kinase (JAK) inhibitor used as a disease‑modifying therapy for several immune‑mediated inflammatory conditions. It is approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ulcerative colitis (UC). By modulating the JAK‑STAT signaling pathway, Xeljanz reduces inflammation and immune system overactivity, thereby alleviating symptoms and preventing disease progression.\u003c\/p\u003e\r\n\u003cp data-start=\"735\" data-end=\"854\"\u003e\u003cem data-start=\"735\" data-end=\"854\"\u003eReference: U.S. FDA Xeljanz Prescribing Information; ClinicalTrials.gov (e.g., NCT01039688, NCT01375647, NCT01463232)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"856\" data-end=\"859\"\u003e\r\n\u003ch3 data-start=\"861\" data-end=\"912\"\u003eWhat are the other popular names for Xeljanz?\u003c\/h3\u003e\r\n\u003cp data-start=\"913\" data-end=\"1177\"\u003eXeljanz is the brand name for the active ingredient \u003cstrong data-start=\"965\" data-end=\"980\"\u003etofacitinib\u003c\/strong\u003e. In addition to Xeljanz, the extended‑release formulation is marketed as \u003cstrong data-start=\"1054\" data-end=\"1068\"\u003eXeljanz XR\u003c\/strong\u003e in some regions. The generic name, tofacitinib, is also used in scientific literature and clinical practice.\u003c\/p\u003e\r\n\u003cp data-start=\"1179\" data-end=\"1213\"\u003e\u003cem data-start=\"1179\" data-end=\"1213\"\u003eReference: U.S. FDA; MedlinePlus\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1215\" data-end=\"1218\"\u003e\r\n\u003ch3 data-start=\"1220\" data-end=\"1269\"\u003eWhat is the drug classification of Xeljanz?\u003c\/h3\u003e\r\n\u003cp data-start=\"1270\" data-end=\"1516\"\u003eXeljanz is classified as an \u003cstrong data-start=\"1298\" data-end=\"1335\"\u003eoral Janus kinase (JAK) inhibitor\u003c\/strong\u003e. It falls under the therapeutic category of immunomodulatory agents and is used to modify the disease course in autoimmune conditions by targeting intracellular signaling pathways.\u003c\/p\u003e\r\n\u003cp data-start=\"1518\" data-end=\"1613\"\u003e\u003cem data-start=\"1518\" data-end=\"1613\"\u003eReference: U.S. FDA; World Health Organization (WHO) guidelines on immunomodulatory therapies\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1615\" data-end=\"1618\"\u003e\r\n\u003ch3 data-start=\"1620\" data-end=\"1664\"\u003eWhat is the mode of action of Xeljanz?\u003c\/h3\u003e\r\n\u003cp data-start=\"1665\" data-end=\"2112\"\u003eXeljanz works by inhibiting one or more of the Janus kinase enzymes (primarily JAK1 and JAK3, and to a lesser extent JAK2). This inhibition blocks the JAK‑STAT pathway, which is essential for the signaling of various pro‑inflammatory cytokines (such as interleukins and interferons). The result is a reduction in inflammatory activity and modulation of the immune response, leading to improved clinical outcomes in conditions like RA, PsA, and UC.\u003c\/p\u003e\r\n\u003cp data-start=\"2114\" data-end=\"2189\"\u003e\u003cem data-start=\"2114\" data-end=\"2189\"\u003eReference: PubMed (e.g., O’Shea et al., 2013 on JAK inhibitors); U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2191\" data-end=\"2194\"\u003e\r\n\u003ch3 data-start=\"2196\" data-end=\"2239\"\u003eWhat are the primary uses of Xeljanz?\u003c\/h3\u003e\r\n\u003cp data-start=\"2240\" data-end=\"2283\"\u003eXeljanz is approved for the treatment of:\u003c\/p\u003e\r\n\u003cul data-start=\"2284\" data-end=\"2741\"\u003e\r\n\u003cli data-start=\"2284\" data-end=\"2486\"\u003e\n\u003cstrong data-start=\"2286\" data-end=\"2316\"\u003eRheumatoid Arthritis (RA):\u003c\/strong\u003e To reduce joint inflammation, pain, and prevent joint damage in patients with moderate to severe RA who have had an inadequate response or intolerance to methotrexate.\u003c\/li\u003e\r\n\u003cli data-start=\"2487\" data-end=\"2620\"\u003e\n\u003cstrong data-start=\"2489\" data-end=\"2519\"\u003ePsoriatic Arthritis (PsA):\u003c\/strong\u003e To improve signs and symptoms, physical function, and quality of life in patients with active PsA.\u003c\/li\u003e\r\n\u003cli data-start=\"2621\" data-end=\"2741\"\u003e\n\u003cstrong data-start=\"2623\" data-end=\"2651\"\u003eUlcerative Colitis (UC):\u003c\/strong\u003e To induce and maintain remission in adult patients with moderately to severely active UC.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2743\" data-end=\"2784\"\u003e\u003cem data-start=\"2743\" data-end=\"2784\"\u003eReference: U.S. FDA; ClinicalTrials.gov\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2786\" data-end=\"2789\"\u003e\r\n\u003ch3 data-start=\"2791\" data-end=\"2859\"\u003eWhat is the recommended dosage and administration for Xeljanz?\u003c\/h3\u003e\r\n\u003cul data-start=\"2860\" data-end=\"3389\"\u003e\r\n\u003cli data-start=\"2860\" data-end=\"3063\"\u003e\n\u003cstrong data-start=\"2862\" data-end=\"2915\"\u003eFor Rheumatoid Arthritis and Psoriatic Arthritis:\u003c\/strong\u003e\r\n\u003cul data-start=\"2920\" data-end=\"3063\"\u003e\r\n\u003cli data-start=\"2920\" data-end=\"2989\"\u003e\n\u003cstrong data-start=\"2922\" data-end=\"2954\"\u003eXeljanz (Immediate-Release):\u003c\/strong\u003e Typically, \u003cstrong data-start=\"2966\" data-end=\"2986\"\u003e5 mg twice daily\u003c\/strong\u003e.\u003c\/li\u003e\r\n\u003cli data-start=\"2992\" data-end=\"3063\"\u003e\n\u003cstrong data-start=\"2994\" data-end=\"3028\"\u003eXeljanz XR (Extended-Release):\u003c\/strong\u003e Generally, \u003cstrong data-start=\"3040\" data-end=\"3060\"\u003e11 mg once daily\u003c\/strong\u003e.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3064\" data-end=\"3221\"\u003e\n\u003cstrong data-start=\"3066\" data-end=\"3093\"\u003eFor Ulcerative Colitis:\u003c\/strong\u003e\r\n\u003cul data-start=\"3098\" data-end=\"3221\"\u003e\r\n\u003cli data-start=\"3098\" data-end=\"3163\"\u003e\n\u003cstrong data-start=\"3100\" data-end=\"3120\"\u003eInduction Phase:\u003c\/strong\u003e 10 mg twice daily for the first 8 weeks.\u003c\/li\u003e\r\n\u003cli data-start=\"3166\" data-end=\"3221\"\u003e\n\u003cstrong data-start=\"3168\" data-end=\"3190\"\u003eMaintenance Phase:\u003c\/strong\u003e 5 mg twice daily thereafter.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3222\" data-end=\"3389\"\u003e\n\u003cstrong data-start=\"3224\" data-end=\"3243\"\u003eAdministration:\u003c\/strong\u003e\r\n\u003cul data-start=\"3248\" data-end=\"3389\"\u003e\r\n\u003cli data-start=\"3248\" data-end=\"3389\"\u003eXeljanz is taken orally, with or without food. Consistent daily dosing at the same time is recommended to maintain therapeutic drug levels.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3391\" data-end=\"3497\"\u003e\u003cem data-start=\"3391\" data-end=\"3497\"\u003eReference: U.S. FDA Xeljanz Prescribing Information; ClinicalTrials.gov (e.g., NCT01039688, NCT01463232)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"3499\" data-end=\"3502\"\u003e\r\n\u003ch3 data-start=\"3504\" data-end=\"3564\"\u003eWhat prescribing information is important for Xeljanz?\u003c\/h3\u003e\r\n\u003cul data-start=\"3565\" data-end=\"4293\"\u003e\r\n\u003cli data-start=\"3565\" data-end=\"3754\"\u003e\n\u003cstrong data-start=\"3567\" data-end=\"3583\"\u003eIndications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3588\" data-end=\"3754\"\u003e\r\n\u003cli data-start=\"3588\" data-end=\"3754\"\u003eXeljanz is indicated for adult patients with RA, PsA, or UC who have shown inadequate response or intolerance to conventional therapies (e.g., methotrexate for RA).\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3755\" data-end=\"3931\"\u003e\n\u003cstrong data-start=\"3757\" data-end=\"3779\"\u003eContraindications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3784\" data-end=\"3931\"\u003e\r\n\u003cli data-start=\"3784\" data-end=\"3931\"\u003eIt is contraindicated in patients with severe infections, active tuberculosis, or known hypersensitivity to tofacitinib or any of its components.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3932\" data-end=\"4085\"\u003e\n\u003cstrong data-start=\"3934\" data-end=\"3949\"\u003eMonitoring:\u003c\/strong\u003e\r\n\u003cul data-start=\"3954\" data-end=\"4085\"\u003e\r\n\u003cli data-start=\"3954\" data-end=\"4085\"\u003eRegular monitoring of complete blood counts, liver enzymes, lipid profiles, and assessment for signs of infection is recommended.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4086\" data-end=\"4293\"\u003e\n\u003cstrong data-start=\"4088\" data-end=\"4115\"\u003eSpecial Considerations:\u003c\/strong\u003e\r\n\u003cul data-start=\"4120\" data-end=\"4293\"\u003e\r\n\u003cli data-start=\"4120\" data-end=\"4203\"\u003ePatients should be evaluated for latent tuberculosis before starting treatment.\u003c\/li\u003e\r\n\u003cli data-start=\"4206\" data-end=\"4293\"\u003eUse with caution in patients with a history of cardiovascular disease and malignancy.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4295\" data-end=\"4404\"\u003e\u003cem data-start=\"4295\" data-end=\"4404\"\u003eReference: U.S. FDA; National Institutes of Health (NIH); American College of Rheumatology (ACR) guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"4406\" data-end=\"4409\"\u003e\r\n\u003ch3 data-start=\"4411\" data-end=\"4507\"\u003eWhat safety information, side effects, warnings, and cautions are associated with Xeljanz?\u003c\/h3\u003e\r\n\u003cul data-start=\"4508\" data-end=\"5534\"\u003e\r\n\u003cli data-start=\"4508\" data-end=\"4617\"\u003e\n\u003cstrong data-start=\"4510\" data-end=\"4534\"\u003eCommon Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"4539\" data-end=\"4617\"\u003e\r\n\u003cli data-start=\"4539\" data-end=\"4617\"\u003eUpper respiratory tract infections, headache, diarrhea, and nasopharyngitis.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4618\" data-end=\"4753\"\u003e\n\u003cstrong data-start=\"4620\" data-end=\"4645\"\u003eSerious Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"4650\" data-end=\"4753\"\u003e\r\n\u003cli data-start=\"4650\" data-end=\"4753\"\u003eIncreased risk of serious infections (including tuberculosis), blood clots, and certain malignancies.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4754\" data-end=\"5374\"\u003e\n\u003cstrong data-start=\"4756\" data-end=\"4780\"\u003eWarnings \u0026amp; Cautions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4785\" data-end=\"5374\"\u003e\r\n\u003cli data-start=\"4785\" data-end=\"4925\"\u003e\n\u003cstrong data-start=\"4787\" data-end=\"4802\"\u003eInfections:\u003c\/strong\u003e There is an increased risk of opportunistic infections; patients should be screened for latent TB and monitored closely.\u003c\/li\u003e\r\n\u003cli data-start=\"4928\" data-end=\"5028\"\u003e\n\u003cstrong data-start=\"4930\" data-end=\"4956\"\u003eThromboembolic Events:\u003c\/strong\u003e Use caution in patients with risk factors for venous thromboembolism.\u003c\/li\u003e\r\n\u003cli data-start=\"5031\" data-end=\"5153\"\u003e\n\u003cstrong data-start=\"5033\" data-end=\"5048\"\u003eMalignancy:\u003c\/strong\u003e Long-term immunosuppression may increase the risk of cancers, particularly lymphomas and skin cancers.\u003c\/li\u003e\r\n\u003cli data-start=\"5156\" data-end=\"5256\"\u003e\n\u003cstrong data-start=\"5158\" data-end=\"5182\"\u003eCardiovascular Risk:\u003c\/strong\u003e Caution is advised in patients with a history of cardiovascular events.\u003c\/li\u003e\r\n\u003cli data-start=\"5259\" data-end=\"5374\"\u003e\n\u003cstrong data-start=\"5261\" data-end=\"5279\"\u003eLipid Changes:\u003c\/strong\u003e Xeljanz may cause an increase in cholesterol levels; periodic lipid monitoring is recommended.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5375\" data-end=\"5534\"\u003e\n\u003cstrong data-start=\"5377\" data-end=\"5405\"\u003ePregnancy and Lactation:\u003c\/strong\u003e\r\n\u003cul data-start=\"5410\" data-end=\"5534\"\u003e\r\n\u003cli data-start=\"5410\" data-end=\"5534\"\u003eXeljanz is not recommended during pregnancy or breastfeeding due to potential teratogenic effects and limited safety data.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5536\" data-end=\"5613\"\u003e\u003cem data-start=\"5536\" data-end=\"5613\"\u003eReference: U.S. FDA Xeljanz Prescribing Information; PubMed; ACR Guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5615\" data-end=\"5618\"\u003e\r\n\u003ch3 data-start=\"5620\" data-end=\"5683\"\u003eWhat drug interactions should be considered with Xeljanz?\u003c\/h3\u003e\r\n\u003cul data-start=\"5684\" data-end=\"6307\"\u003e\r\n\u003cli data-start=\"5684\" data-end=\"5829\"\u003e\n\u003cstrong data-start=\"5686\" data-end=\"5709\"\u003eImmunosuppressants:\u003c\/strong\u003e\r\n\u003cul data-start=\"5714\" data-end=\"5829\"\u003e\r\n\u003cli data-start=\"5714\" data-end=\"5829\"\u003eConcomitant use with other potent immunosuppressive agents (e.g., biologics) may increase the risk of infections.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5830\" data-end=\"5998\"\u003e\n\u003cstrong data-start=\"5832\" data-end=\"5854\"\u003eCYP3A4 Inhibitors:\u003c\/strong\u003e\r\n\u003cul data-start=\"5859\" data-end=\"5998\"\u003e\r\n\u003cli data-start=\"5859\" data-end=\"5998\"\u003eDrugs such as ketoconazole or clarithromycin may increase the plasma concentration of tofacitinib, potentially enhancing adverse effects.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5999\" data-end=\"6122\"\u003e\n\u003cstrong data-start=\"6001\" data-end=\"6014\"\u003eVaccines:\u003c\/strong\u003e\r\n\u003cul data-start=\"6019\" data-end=\"6122\"\u003e\r\n\u003cli data-start=\"6019\" data-end=\"6122\"\u003eLive vaccines should generally be avoided during treatment with Xeljanz due to the risk of infection.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"6123\" data-end=\"6307\"\u003e\n\u003cstrong data-start=\"6125\" data-end=\"6147\"\u003eOther Medications:\u003c\/strong\u003e\r\n\u003cul data-start=\"6152\" data-end=\"6307\"\u003e\r\n\u003cli data-start=\"6152\" data-end=\"6307\"\u003eAlways inform your healthcare provider of all concomitant medications (including over-the-counter drugs and supplements) to avoid potential interactions.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"6309\" data-end=\"6371\"\u003e\u003cem data-start=\"6309\" data-end=\"6371\"\u003eReference: U.S. FDA; Clinical Pharmacology Reviews on PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"6373\" data-end=\"6376\"\u003e\r\n\u003ch3 data-start=\"6378\" data-end=\"6417\"\u003eFrequently Asked Questions (FAQs)\u003c\/h3\u003e\r\n\u003cp data-start=\"6419\" data-end=\"6592\"\u003e\u003cstrong data-start=\"6419\" data-end=\"6465\"\u003eQ: How quickly does Xeljanz begin to work?\u003c\/strong\u003e\u003cbr data-start=\"6465\" data-end=\"6468\"\u003eA: Some patients may notice improvement in symptoms within 2–4 weeks, although maximum benefits may take longer to manifest.\u003c\/p\u003e\r\n\u003cp data-start=\"6594\" data-end=\"6959\"\u003e\u003cstrong data-start=\"6594\" data-end=\"6638\"\u003eQ: Can Xeljanz be used as a monotherapy?\u003c\/strong\u003e\u003cbr data-start=\"6638\" data-end=\"6641\"\u003eA: For rheumatoid arthritis and psoriatic arthritis, Xeljanz is often used in patients with an inadequate response to conventional therapy, but it can be used as monotherapy or in combination with methotrexate. For ulcerative colitis, it is used in patients who have not responded adequately to conventional treatment.\u003c\/p\u003e\r\n\u003cp data-start=\"6961\" data-end=\"7223\"\u003e\u003cstrong data-start=\"6961\" data-end=\"7020\"\u003eQ: What precautions should I take regarding infections?\u003c\/strong\u003e\u003cbr data-start=\"7020\" data-end=\"7023\"\u003eA: Patients should be screened for latent tuberculosis before starting Xeljanz and monitored for signs of infection during treatment. Contact your doctor immediately if you develop signs of infection.\u003c\/p\u003e\r\n\u003cp data-start=\"7225\" data-end=\"7417\"\u003e\u003cstrong data-start=\"7225\" data-end=\"7265\"\u003eQ: Is Xeljanz safe during pregnancy?\u003c\/strong\u003e\u003cbr data-start=\"7265\" data-end=\"7268\"\u003eA: Xeljanz is not recommended during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception during treatment.\u003c\/p\u003e\r\n\u003cp data-start=\"7419\" data-end=\"7598\"\u003e\u003cstrong data-start=\"7419\" data-end=\"7459\"\u003eQ: How should I manage missed doses?\u003c\/strong\u003e\u003cbr data-start=\"7459\" data-end=\"7462\"\u003eA: If you miss a dose, take it as soon as you remember. If it is near the time of your next dose, skip the missed dose—do not double up.\u003c\/p\u003e\r\n\u003cp data-start=\"7600\" data-end=\"7689\"\u003e\u003cem data-start=\"7600\" data-end=\"7689\"\u003eReference: U.S. FDA Xeljanz Prescribing Information; ACR Guidelines; ClinicalTrials.gov\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"7691\" data-end=\"7694\"\u003e\r\n\u003ch3 data-start=\"7696\" data-end=\"7787\"\u003eWhere can I find additional clinical evidence and detailed information about Xeljanz?\u003c\/h3\u003e\r\n\u003cp data-start=\"7788\" data-end=\"7870\"\u003eFor more comprehensive data on Xeljanz’s efficacy, safety, and dosing, refer to:\u003c\/p\u003e\r\n\u003cul data-start=\"7871\" data-end=\"8218\"\u003e\r\n\u003cli data-start=\"7871\" data-end=\"7959\"\u003e\n\u003cstrong data-start=\"7873\" data-end=\"7925\"\u003eU.S. Food and Drug Administration (FDA) Website:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"7926\" data-end=\"7957\"\u003eFDA.gov\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"7960\" data-end=\"8055\"\u003e\n\u003cstrong data-start=\"7962\" data-end=\"7985\"\u003eClinicalTrials.gov:\u003c\/strong\u003e (e.g., NCT01039688 for RA, NCT01375647 for PsA, NCT01463232 for UC)\u003c\/li\u003e\r\n\u003cli data-start=\"8056\" data-end=\"8122\"\u003e\n\u003cstrong data-start=\"8058\" data-end=\"8069\"\u003ePubMed:\u003c\/strong\u003e For peer‑reviewed research articles on tofacitinib\u003c\/li\u003e\r\n\u003cli data-start=\"8123\" data-end=\"8218\"\u003e\u003cstrong data-start=\"8125\" data-end=\"8218\"\u003eAmerican College of Rheumatology (ACR) and National Institutes of Health (NIH) Guidelines\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"8220\" data-end=\"8274\"\u003e\u003cem data-start=\"8220\" data-end=\"8274\"\u003eReference: U.S. FDA; ClinicalTrials.gov; PubMed; ACR\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"8276\" data-end=\"8279\"\u003e\r\n\u003ch3 data-start=\"8281\" data-end=\"8301\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"8302\" data-end=\"8934\"\u003e\u003cstrong data-start=\"8302\" data-end=\"8327\"\u003eXeljanz (tofacitinib)\u003c\/strong\u003e is a powerful oral JAK inhibitor that offers effective symptom relief and disease modification for patients with rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. By blocking key pathways in the immune response, Xeljanz reduces inflammation and improves clinical outcomes. However, its use is associated with an increased risk of infections, thromboembolic events, and potential malignancies, necessitating careful patient selection, thorough monitoring, and management of drug interactions. Always consult your healthcare provider to ensure Xeljanz is appropriate for your treatment plan.\u003c\/p\u003e\r\n\u003cp data-start=\"8936\" data-end=\"9154\"\u003e\u003cem data-start=\"8936\" data-end=\"9154\"\u003eDisclaimer: This guide is intended for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e","brand":"EZ Chemist","offers":[{"title":"5mg","offer_id":51735708598555,"sku":"Generic Xeljanz (Tofacitinib) 5mg x 30 tablets-5mg","price":78.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/ezchemist.com\/products\/xeljanz","provider":"EZ Chemist","version":"1.0","type":"link"}